壹快评｜大批中成药将退出市场，关乎百姓健康不妨少些“爱国叙事”

Core Viewpoint - The value of traditional Chinese medicine (TCM) lies in clinical efficacy and scientific evidence, rather than national pride or patriotic narratives [1] Regulatory Changes - A new regulation from the National Medical Products Administration mandates that any existing TCM products with unclear contraindications, adverse reactions, or precautions will not be re-registered after July 1, 2026 [1] - This regulation aims to eliminate "zombie" licenses, which refer to products that have marketing approval but are not produced or sold, lacking post-marketing surveillance and adverse reaction data [1][2] Industry Response - Many industry insiders support the new regulation, indicating it encourages pharmaceutical companies to prioritize drug safety and responsibility [3] - The 2022 National TCM Regulatory Blue Book reports approximately 2,400 TCM production companies in China, with over 9,000 TCM varieties, many of which suffer from low clinical value and redundancy [3] Future Directions for TCM Companies - TCM companies have three options: enhance safety research for core products to retain licenses, apply for modified new drug status for promising products, or abandon low-value products [4] - The outcome of these choices will accelerate the elimination of inferior products, leaving only those that withstand scientific scrutiny and market testing [4] Conclusion on TCM Development - The new registration requirements are seen as a necessary step towards high-quality development in the TCM industry, promoting a shift from quantity to quality [3][4] - The emphasis on scientific validation over emotional or nationalistic narratives is crucial for the future of TCM [4]